FDA approvals are significant milestones for biotech companies, often leading to increased investor confidence and stock price appreciation. The approval of UDENYCA ONBODY is directly related to Coherus BioSciences' core business, making it highly relevant and important news for the company. The positive impact on the stock price is likely, although market conditions and broader sector performance can also influence the movement.